CALCULATE YOUR SIP RETURNS

Emcure Pharmaceuticals Enters OTC Wellness Market with Arth Supplements Expansion

Written by: Team Angel OneUpdated on: Mar 11, 2025, 2:45 PM IST
Emcure Pharmaceuticals expands its OTC portfolio with Arth supplements, introducing three new products for intimate care, sleep quality, and cognitive health.
Emcure Pharmaceuticals Enters OTC Wellness Market with Arth Supplements Expansion
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Emcure Pharmaceuticals Ltd, an Indian pharmaceutical company focused on women’s health, has expanded its over-the-counter (OTC) portfolio with the Arth supplement range. The company has introduced three new products to address intimate care, sleep quality, and cognitive health. 

The expansion is an entry into the daily wellness segment, combining traditional Indian herbs like Brahmi with modern scientific formulations, as per the filing.

New Additions to the Arth Range

The newly introduced supplements under the Arth brand include:

  • Intimate Care – A supplement designed to address issues in intimate areas.
  • Sleep Support Gummies – A product aimed at improving sleep quality and relaxation.
  • Brain Fog Aid – A supplement formulated to support cognitive function and focus.

To amplify awareness around women’s health, Emcure has partnered with Vidya Balan, for the same. On joining hands with Emcure, Balan expressed her enthusiasm for the brand’s mission. She talked about how women’s health often takes a backseat despite their crucial role in families and society. She hopes that her association will encourage women to prioritize self-care through informed choices.

Market Position and Expansion 

Emcure Pharmaceuticals, founded in 1981 and headquartered in Pune, is ranked as the 12th largest pharmaceutical company in India based on domestic sales (MAT June 2024). The company operates in over 70 countries, including Europe and Canada, with a focus on R&D-driven pharmaceutical development. The launch of the Arth range is an expansion into the non-prescription wellness segment.

Market Performance

As of March 11, 2025, 09:30 AM,  Emcure Pharmaceuticals Ltd was trading at ₹942.80, showing a 0.28% increase (+₹2.60). The stock has recorded a 15.12% decline over the past month and a 33.99% drop in the last six months.

Conclusion

The launch of Arth supplements broadens Emcure’s product portfolio beyond prescription drugs. The company is expanding its OTC offerings, focusing on science-backed health solutions in the wellness market. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Mar 11, 2025, 2:45 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 3 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 3 Cr+ happy customers